Note*: This report requires 5-10 business days to complete.
DelveInsight’s HIV-associated Lipodystrophy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and HIV-associated Lipodystrophy forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of HIV-associated Lipodystrophy till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global HIV-associated Lipodystrophy market.
• Identifying patient populations in the global “HIV-associated Lipodystrophymarket to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for HIV-associated Lipodystrophy therapeutics in each of the markets covered.
• To understand the future market competition in the global HIV-associated Lipodystrophy therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides HIV-associated Lipodystrophy for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
'
Table of Contents
• HIV-associated Lipodystrophy overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global HIV-associated Lipodystrophy Market
• Global Epidemiology of HIV-associated Lipodystrophy Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: HIV-associated Lipodystrophy Drug Sales (USD Millions)-2023
• Table 6: Global Epidemiology of HIV-associated Lipodystrophy (2013-2023)
• Table 7: HIV-associated Lipodystrophy Global Market (USD Millions), (2013-2015)
• Table 8: HIV-associated Lipodystrophy Global Market (USD Millions), (2016-2023)
• Table 9: HIV-associated Lipodystrophy US Market (USD Millions), (2013-2015)
• Table 10: HIV-associated Lipodystrophy US Market (USD Millions), (2016-2023)
• Table 11: HIV-associated Lipodystrophy Germany Market (USD Millions), (2013-2015)
• Table 12: HIV-associated Lipodystrophy Germany Market (USD Millions), (2016-2023)
• Table 13: HIV-associated Lipodystrophy United Kingdom Market (USD Millions), (2013-2015)
• Table 14: HIV-associated Lipodystrophy United Kingdom Market (USD Millions), (2016-2023)
• Table 15: HIV-associated Lipodystrophy France Market (USD Millions), (2013-2015)
• Table 16: HIV-associated Lipodystrophy France Market (USD Millions), (2016-2023)
• Table 17: HIV-associated Lipodystrophy Italy Market (USD Millions), (2013-2015)
• Table 18: HIV-associated Lipodystrophy Italy Market (USD Millions), (2016-2023)
• Table 19: HIV-associated Lipodystrophy Spain Market (USD Millions), (2013-2015)
• Table 20: HIV-associated Lipodystrophy Spain Market (USD Millions), (2016-2023)
• Table 21: HIV-associated Lipodystrophy Japan Market (USD Millions), (2013-2015)
• Table 22: HIV-associated Lipodystrophy Japan Market (USD Millions), (2016-2023)
• Table 23: HIV-associated Lipodystrophy ROW Market (USD Millions), (2013-2015)
• Table 24: HIV-associated Lipodystrophy ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: HIV-associated Lipodystrophy Drug Sales (USD Millions)-2023
• Figure 2: Global Epidemiology of HIV-associated Lipodystrophy (2013-2023)
• Figure 3: HIV-associated Lipodystrophy Global Market (USD Millions), (2013-2015)
• Figure 4: HIV-associated Lipodystrophy Global Market (USD Millions), (2016-2023)
• Figure 5: HIV-associated Lipodystrophy US Market (USD Millions), (2013-2015)
• Figure 6: HIV-associated Lipodystrophy US Market (USD Millions), (2016-2023)
• Figure 7: HIV-associated Lipodystrophy Germany Market (USD Millions), (2013-2015)
• Figure 8: HIV-associated Lipodystrophy Germany Market (USD Millions), (2016-2023)
• Figure 9: HIV-associated Lipodystrophy United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: HIV-associated Lipodystrophy United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: HIV-associated Lipodystrophy France Market (USD Millions), (2013-2015)
• Figure 12: HIV-associated Lipodystrophy France Market (USD Millions), (2016-2023)
• Figure 13: HIV-associated Lipodystrophy Italy Market (USD Millions), (2013-2015)
• Figure 14: HIV-associated Lipodystrophy Italy Market (USD Millions), (2016-2023)
• Figure 15: HIV-associated Lipodystrophy Spain Market (USD Millions), (2013-2015)
• Figure 16: HIV-associated Lipodystrophy Spain Market (USD Millions), (2016-2023)
• Figure 17: HIV-associated Lipodystrophy Japan Market (USD Millions), (2013-2015)
• Figure 18: HIV-associated Lipodystrophy Japan Market (USD Millions), (2015-2023)
• Figure 19: HIV-associated Lipodystrophy ROW Market (USD Millions), (2013-2015)
• Figure 20: HIV-associated Lipodystrophy ROW Market (USD Millions), (2016-2023)
• Theratechnologies Inc.
• Abbott Laboratories
• GlaxoSmithKline Plc
• Gilead Sciences Inc.
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Amylin Pharmaceuticals Inc.
• Amgen Inc.
• Alfa Wassermann S.p.A
• AbbVie Inc.
